

27th April 2024

To,

BSE LIMITED Phiroze Jeejeebhoy Towers Dalal Street Mumbai - 400001 THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED

Exchange Plaza, 5th Floor, Plot No. C/1, G Block Bandra-Kurla Complex, Bandra (East) Mumbai - 400051

Dear Sir,

Sub: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to the captioned subject, we would like to inform you that the Company has received an Orders dated 26th April 2024 from Commissioner of Income-tax (Appeals) [CIT(A)] for FY 1983-84, FY1988-89, FY1989-90 to FY1991-92, FY1998-99 and FY1999-00, wherein the CIT(A) has directed the Assessing Officer ('AO') to grant additional interest on refund due to GSK. The relevant details to be is disclosed is as under:

Sr no	Particulars	Details
1	Name of the authority	Commissioner of Income-tax (Appeals) [CIT(A)], Income Tax Department, National Faceless Appeal Centre (NFAC), Delhi
2	Nature and details of the action(s) taken, initiated or order(s) passed	Orders dated 26 April 2024 passed under Section 250 of the Income Tax Act, 1961 directing the Assessing Officer to grant additional interest on refund to the company for FY 1983-84, FY1988-89, FY1989-90 to FY1991-92, FY1998-99 and FY1999- 00 (No demand payable by the Company)
3	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	26 th April 2024
4	Details of violation(s) / contravention(s) committed or alleged to be committed	None.
5	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible	No impact on GSK.

Kindly take the same on the record.

Thanking you,

Yours faithfully For GlaxoSmithKline Pharmaceuticals Limited

Ajay Nadkarni Vice President – Administration, Real Estate & Company Secretary